DIAMEDICA INC. (the “Corporation”) - and - Stephen Mullie (the “Shareholder”)Voting Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • Manitoba
NOW THEREFORE, in consideration of the premises and of the mutual agreement and covenants set forth herein and in the Investment Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
OFFICE LEASEOffice Lease • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • Minnesota
PARTIES: ONE TWO HOLDING LLC, A DELAWARE LIMITED LIABILITY COMPANY “Landlord” DIAMEDICA USA INC., A DELAWARE CORPORATION “Tenant”
GPEx®-DERIVED CELL LINE SALE AGREEMENTLine Sale Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
This GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made as of this 2nd day of February, 2012 (“Effective Date”), by and between DiaMedica Inc., a Manitoba corporation, with a place of business at 200 – 135 Innovation Drive, Winnipeg, Manitoba, R3T 6A8, Canada (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
OPTION AGREEMENT This Agreement dated as of the ● day of ●, ●, BETWEEN: DIAMEDICA THERAPEUTICS INC. a corporation incorporated under the laws of Canada, (hereinafter called the “Corporation”), OF THE FIRST PART, - and - of the • of ●, in the ● of ●,...Option Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • British Columbia
WHEREAS the Participant is a bona fide Senior Officer, Director, Employee, Management Company Employee or Consultant of the Corporation or any subsidiary of the Corporation;
SUPPLY AGREEMENTSupply Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
This Supply Agreement (“Agreement”) is entered into as of September 27, 2018 (the “Effective Date”), by and between DiaMedica Therapeutics, Inc., a corporation organized and existing under the laws of Canada with offices at c/o DiaMedica USA, Inc., Two Carlson Parkway, Suite 260, Minneapolis, Minnesota 55447, USA (“Licensor”) and Ahon Pharmaceutical co., Ltd., a corporation organized and existing under the laws of China, having a place of business at No. 55, Songshan Rd., Jinzhou, Liaoning Province, China (“Licensee”). Licensor and Licensee may each be referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made as of September 27, 2018 (the “Effective Date”), by and between DiaMedica Therapeutics, Inc., a corporation organized and existing under the laws of Canada with offices at c/o DiaMedica USA, Inc., Two Carlson Parkway, Suite 260, Minneapolis, Minnesota 55447, USA (“DiaMedica”), and Ahon Pharmaceutical co., Ltd., a corporation organized and existing under the laws of China, having a place of business at No. 55, Songshan Rd., Jinzhou, Liaoning Province, China (“Ahon”). DiaMedica and Ahon are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations
This First Amendment to GPEx® Development and Manufacturing Agreement (this “Amendment”), is made as of this 10th day of April, 2017 (“Amendment Effective Date”), by and between DiaMedica Therapeutics Inc., a Manitoba corporation, with a place of business at Two Carlson Parkway, Suite 165, Minneapolis, MN 55447 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, NJ 08873, USA (“Catalent”).
FIRST AMENDMENT TO LEASELease • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations
SHAREHOLDER RIGHTS PLAN AGREEMENTShareholder Rights Plan Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • Ontario
NOW THEREFORE, in consideration of the premises and the respective covenants and agreements set forth herein the parties hereby agree as follows:
SUPPLEMENTAL TO LEASE AGREEMENTLease Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations
